A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Researchers are enrolling people with locally advanced or metastatic cancer who are prescribed atezolizumab (alone or with other approved treatments). The study will monitor blood levels to adjust infusion schedules, aiming to see if lower or less frequent doses can be given without reducing effectiveness, over a period of up to 2 years.
Phase 1 Study with Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants with Mesothelin-Expressing Solid Tumors Including Mesothelioma
Researchers at NCI are developing a new investigational treatment known as TNhYP218 CAR T cells to target and kill tumor cells in people with solid tumors and with those that have high levels of mesothelin (MSLN) including mesothelioma. The study team collects immune cells (T cells); the T cells are genetically modified to target and kill tumor cells to potentially shrink the tumor.
CAR-T Cell Treatment for Patients with Glypican-3 (GPC3) Positive HCC (A Type of Liver Cancer)
Evaluation for NCI Surgery Branch Clinical Research Protocols
Doctors at the National Cancer Institute (NCI) are looking for volunteers with metastatic cancers, including breast, ovarian, endometrial, gastrointestinal, genitourinary, hepatobiliary, pancreatic, melanoma, non-small cell lung cancer (NSCLC), and multiple myeloma with solid masses. Potential participants will be evaluated with new immunotherapy treatments utilizing cell transfer immunotherapies in a research trial.
Men at High Genetic Risk for Prostate Cancer
Clinical and Scientific Assessment of Pain and Painful Disorders
Researchers in the National Center for Complementary and Integrative Health at the National Institutes of Health seek healthy volunteers to participate in a study investigating how our brain responds to pain. This study will allow researchers to collect information that may be used to learn more about pain disorders and how we respond to painful experiences.